Association of Disease Severity with IL-1 levels in Methotrexate-treated Psoriasis Patients

Scandinavian Journal of Immunology

Volumn 78, Issue 6, 2013, Pages 545-553

  Tamilselvi, E ^a   Haripriya, D ^a   Hemamalini, M ^a   Pushpa, G ^a   Swapna, S ^a  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; METHOTREXATE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; SCORING SYSTEM; SKIN BIOPSY; TH17 CELL;

ADOLESCENT; ADULT; AGED; CELL DIFFERENTIATION; FEMALE; HUMANS; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; SKIN; TH17 CELLS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888420482     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12117     Document Type: Article

References (58)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;61:496-509.
2. Sabat R, Philipp S, Höflich C et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007;16:779-98.
3. Christensen TE, Callis KP, Papenfuss J et al. Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J Invest Dermatol 2006;126:2397-403.
4. McKenzie RC, Sauder DN. The role of keratinocyte cytokines in inflammation and immunity. J Invest Dermatol 1990;95(Suppl. 6):105S-7S.
5. Baker JN, Jones ML, Mitra RS et al. Modulation keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 1991;139:869-76.
6. Gomi T, Shiohara T, Munakata T, Imanishi K, Nagashima M. Interleukin 1alpha, Tumor necrosis factor alpha and interferon gamma in psoriasis. Arch Dermatol 1991;127:827-30.
7. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993;101:701-5.
8. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz JC. T lymphocytes derived from skin lesion patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from T helper type 1 and T helper type 2 cells. Eur J Immunol 1994;24:2377-82.
9. Olaniran AK, Baker BS, Paige DG, Garioch JJ, Powles AV, Fry L. Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res 1996;288:421-5.
10. Luger TA, Stadler BM, Luger BM et al. Murine epidermal cell derived thymocyte-activating factor resembles murine interleukin 1. J Immunol 1982;128:2147-52.
11. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-50.
12. Dinarello CA. Blocking interleukin-1beta in acute and chronic autoinflammatory diseases. J Intern Med 2011;269:16-28.
13. Nicklin MJH, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1a, interleukin-1b and interleukin-1 receptor antagonist genes. Genomics 1994;19:382-4.
14. Hammerberg C, Bata-Csorgo Z, Voorhees JJ, Cooper KD. IL-1 and IL-1 receptor antagonist regulation during keratinocyte cell cycle and differentiation in normal and psoriatic epidermis. Arch Dermatol Res 1998;290:367-74.
15. Feldmeyer L, Keller M, Niklaus G, Hohl D, Werner S, Beer HD. The inflammasome mediates UVB induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol 2007;17:1140-5.
16. Kupper TS, Ballard DW, Chua AO et al. Human keratinocytes contain mRNA indistinguishable from monocyte interleukin 1 alpha and beta mRNA. Keratinocyte epidermal cell-derived thymocyte-activating factor is identical to interleukin 1. J Exp Med 1986;164:2095-100.
17. Kondo S, Sauder DN, Kono T, Galley KA, McKenzie RC. Differential modulation of interleukin-1 alpha (IL-1 alpha) and interleukin-1 beta (IL-1 beta) in human epidermal keratinocytes by UVB. Exp Dermatol 1994;3:29-39.
18. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009;10:241-7.
19. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996;87:2095-147.
20. Dianarello CA. Role of interleukin-1 and tumor necrosis factor in systemic responses to infection and inflammation. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. New York, NY: Raven Press, 1992: 211-32. ISBN-10: 0881678805.
21. Yano S, Banno T, Walsh R, Blumenberg M. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1. J Cell Physiol 2008;214:1-13.
22. Cohen S, Hurd E, Cush JJ et al. Treatment with interleukin-1 receptor antagonist in combination with methotrexate (MTX): results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
23. Gibbs A, Markham T, Walsh C, Bresnihan B, Veale D, FitzGerald O. Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study. Arthritis Res Ther 2005; 7: P68.
24. Roenigk HH, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis. Revised guidelines. J Am Dermatol, 1988; 19: 145-56.
25. Jeffes EW 3rd, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995;104:183-8.
26. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005;54:273-80.
27. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
28. Bonish B, Jullien D, Dutronc Y et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 2000;165:4076-85.
29. Sigmundsdóttir H, Gudjónsson JE, Jónsdóttir I, Lúdvíksson BR, Valdimarsson H. The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol 2001;126:365-9.
30. Saleh A, Abuhilal M, Cheung B. Methotrexate in Psoriasis: from A to Z. J Turk Acad Dermatol 2010;4:04101r.
31. Schwartz PM, Barnett SK, Atillasoy ES, Milstone LM. Methotrexate induces differentiation of human keratinocytes. Proc Natl Acad Sci USA 1992;89:594-8.
32. Dahlman-Ghozlan K, Ortonne JP, Heilborn JD, Stephansson E. Altered tissue expression pattern of cell adhesion molecules, ICAM-1, E-selectin and VCAM -1, in bullous pemphigoid during methotrexate therapy. Exp Dermatol 2004;13:65-9.
33. Yazici AC, Tursen U, Apa DD et al. The changes in expression of ICAM -3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment. Arch Dermatol Res 2005;297:249-55.
34. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-37.
35. Mark R, Barton SP, Shuttleworth D, Finlay AY. Assessment of disease progress in Psoriasis. Br J Dermatol 2001;144:1121-6.
36. Blalock TD, Varela JC, Gowda S et al. Ischemic skin wound healing models in rats. Wounds 2001;13:35-44.
37. Gniadecki R. Regulation of keratinocyte proliferation. Gen Pharmacol 1998;30:619-22.
38. Kupper lS, Lee F, Birchall Nt Clark S, Dower SK. Interleukin 1 binds to specific receptors on human keratinocytes and induces granulocyte macrophage colony-stimulating factor mRNA and protein. J Clin Invest, 1988; 82:1787-92.
39. Camp RDR, Fincham NJ, Ross J, Bird CR, Gearing AJH. Potent inflammatory properties in human skin of interleukin-l alpha-like material isolated from normal skin. J Invest Dermatol 1990;94:735-41.
40. Kobayashi Y, Appella E, Yamada M, Copeland TD, Oppenheim JJ, Matsushima K. Phosphorylation of Intracellular Precursors of Human IL-1. J lmmunol 1988;140:2279.
41. Takematsu H, Terui T, Ohkohchi K, Tagami H, Suzuki R, Kumagai K. Interleukin-1-like activity in horny layer extracts: decreased activity in scale extracts of psoriasis and sterile dermatoses. Dermatologica 1986; 172:236.
42. Takematsu H, Tagami H. Lack of Correlation Interleukin 1 Levels between Interleukin 6 in Psoriatic Lesional Skin. Tohoku J Exp Med 1994;172:243-52.
43. Yoshinaga Y, Higaki M, Terajima S et al. Detection of inflammatory cytokines in psoriatic skin. Arch Dermatol Res 1995; 287:158-64.
44. Debets R, Hegmans JP, Croughs P et al. The IL-1 system in psoriatic skin. IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 1997; 158:2955-63.
45. Portugal-Cohen M, Horev L, Ruffer C et al. Non-invasive skin biomarkers quantification of psoriasis and atopic dermatitis: cytokines, antioxidants and psoriatic skin auto-fluorescence. Biomed Pharmacother 2012;66:293-9.
46. Fantini F, Magnoni C, Bracci-Laudiero L, Pincelli C. Nerve growth factor is increased in psoriatic skin. J Invest Dermatol 1995;105:854-5.
47. Pincelli C. Nerve growth factor and keratinocytes: a role in psoriasis. Eur J Dermatol 2000; 10:85-90.
48. Ockenfels HM, Nussbaum G, Schneck B, Wagner SN, Haen E, Goos M. The effect of cyclosporin A and FK 506 on the cAMP content in psoriatic keratinocytes. Skin Pharmacol 1996;9:281-8.
49. Stamp LK, Hazlett J, Roberts RL, Frampton C, Highton J, Hessian PA. Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Ther 2012;14:R138.
50. Debets R, Hegmans JP, Troost RJ, Benner R, Prens EP. Enhanced production of biologically active interleukin-1a and interleukin-1b by psoriatic epidermal cells ex vivo: evidence of increased cytosolic interleukin-1b levels and facilitated interleukin-1 release. Eur J Immunol 1995; 25:1624-30.
51. Pietrzak AT, Zalewska A, Chodorowska G et al. Invited critical review: cytokines and anticytokines in psoriasis. Clin Chim Acta 2008;2008(394):7-21.
52. Johansen C, Moeller K, Kragballe K, Iversen L. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol 2007;127:2857-64.
53. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 1997;14:145-53.
54. Chang DM, Weinblatt ME, Schur PH. The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol 1992;19:1678-82.
55. Barrera P, Boerbooms AM, Demacker PN, van de Putte LB, Gallati H, van der Meer JW. Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate. Br J Rheumatol 1994;33:1017-24.
56. Brody M, Böhm I, Bauer R. Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem 1993;31:667-74.
57. Dinarello CA, Ikejima T, Warner SJ et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987;139:1902.
58. Hu Y, Shen F, Crellin NK, Ouyang W. The IL-17 pathway as a major therapeutic target in autoimmune diseases. Ann N Y Acad Sci 2011;1217:60-76.